Skip to main content
Top
Published in: Supportive Care in Cancer 9/2019

01-09-2019 | Care | Correction

Correction to: Human Development Index and its association with staff spiritual care provision: a Middle Eastern oncology study

Authors: Gil Bar-Sela, Michael J. Schultz, Karima Elshamy, Maryam Rassouli, Eran Ben-Arye, Myrna Doumit, Nahla Gafer, Alaa Albashayreh, Ibtisam Ghrayeb, Ibrahim Turker, Gulcin Ozalp, Sultan Kav, Rasha Fahmi, Sophia Nestoros, Hasanein Ghali, Layth Mula-Hussain, Ilana Shazar, Rana Obeidat, Rehana Punjwani, Mohamad Khleif, Gulbeyaz Can, Gonca Tuncel, Haris Charalambous, Safa Faraj, Neophyta Keoppi, Mazin Al-Jadiry, Sergey Postovsky, Ma’an Al-Omari, Samaher Razzaq, Hani Ayyash, Khaled Khader, Rejin Kebudi, Suha Omran, Osaid Rasheed, Mohammed Qadire, Ahmet Ozet, Michael Silbermann

Published in: Supportive Care in Cancer | Issue 9/2019

Login to get access

Excerpt

Correction to: Supportive Care in Cancer
Metadata
Title
Correction to: Human Development Index and its association with staff spiritual care provision: a Middle Eastern oncology study
Authors
Gil Bar-Sela
Michael J. Schultz
Karima Elshamy
Maryam Rassouli
Eran Ben-Arye
Myrna Doumit
Nahla Gafer
Alaa Albashayreh
Ibtisam Ghrayeb
Ibrahim Turker
Gulcin Ozalp
Sultan Kav
Rasha Fahmi
Sophia Nestoros
Hasanein Ghali
Layth Mula-Hussain
Ilana Shazar
Rana Obeidat
Rehana Punjwani
Mohamad Khleif
Gulbeyaz Can
Gonca Tuncel
Haris Charalambous
Safa Faraj
Neophyta Keoppi
Mazin Al-Jadiry
Sergey Postovsky
Ma’an Al-Omari
Samaher Razzaq
Hani Ayyash
Khaled Khader
Rejin Kebudi
Suha Omran
Osaid Rasheed
Mohammed Qadire
Ahmet Ozet
Michael Silbermann
Publication date
01-09-2019
Publisher
Springer Berlin Heidelberg
Keyword
Care
Published in
Supportive Care in Cancer / Issue 9/2019
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-04798-x

Other articles of this Issue 9/2019

Supportive Care in Cancer 9/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine